Navigation Links
Hagens Berman Sobol Shapiro Investigating CellCyte
Date:1/9/2008

SEATTLE, Jan 9 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP (http://www.hbsslaw.com/cellcyte.htm) today announced it is investigating the business practices of CellCyte (OTC Bulletin Board: CCYG) for potential violations of securities laws.

The investigation comes after CellCyte's shares plunged 55 percent after news reports detailed alleged discrepancies in CellCyte CEO Gary Reys' educational and professional credentials.

CellCyte's stock dropped after the company made changes to its Web site concerning Reys' claims to have attended University of Washington and to be a certified public accountant. Media reports also call into question other claims made by Reys concerning his role in other business ventures.

According to published media reports, the changes were prompted by calls from Seattle media questioning the veracity of Reys' claims.

If you are an investor in CellCyte, have information concerning this investigation or if you have any questions concerning CellCyte's actions, please contact plaintiff's counsel at 206-623-7292 or e-mail the law firm at info@hbsslaw.com. You can view additional materials on this investigation at http://www.hbsslaw.com/cellcyte.htm.

Hagens Berman Sobol Shapiro, a law firm with offices in Seattle, San Francisco, Los Angeles, Boston, Chicago and Phoenix, is active in major litigations pending in federal and state courts throughout the United States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and companies, as well as victims of human rights violations. The Hagens Berman Web site (http://www.hbsslaw.com) has more information about the firm.

Contact: Hagens Berman Sobol Shapiro LLP

206-623-7292

info@hbsslaw.com

http://www.hbsslaw.com


'/>"/>
SOURCE Hagens Berman Sobol Shapiro LLP
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
4. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... 30, 2016  The Allen Institute for Cell ... first publicly available collection of gene edited, fluorescently ... key cellular structures with unprecedented clarity. Distributed through ... tools are a crucial first step toward visualizing ... what makes human cells healthy and what goes ...
(Date:11/30/2016)...  Tempus, a technology company focused on supporting ... Cancer Center have partnered to better determine which ... treatment based on next generation genomic and transcriptomic ... research collaboration, Tempus will provide sequencing and analysis ... to Penn. Utilizing next-generation sequencing, machine learning and ...
(Date:11/30/2016)... 30. November 2016   Merck , ... die Unterzeichnung einer Reihe von Vereinbarungen mit ... Evotec AG Screeningleistungen für Mercks Palette genetischer ... Zugriff auf diese Bibliotheken in Kombination mit ... schnelleren Weg zur Ermittlung und Erforschung neuer ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
Breaking Biology News(10 mins):